Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–11 of 11 results
Advanced filters: Author: Qinru Bai Clear advanced filters

  • Most current antidepressants target SERT and NET but often have limited efficacy or side effects. Here, authors reveal how five triple reuptake inhibitors bind to DAT, offering structural insights to guide development of more effective antidepressants.

    • Yue Li
    • Yufei Meng
    • Yan Zhao
    ResearchOpen Access
    Nature Communications
    Volume: 17, P: 1-13

  • Hyperuricemia, a major cause of gout, results from impaired urate excretion. Here, the authors reveal how key anti-gout drugs block URAT1, providing structural insights for designing better hyperuricemia treatments.

    • Zhuoya Yu
    • Tuo Hu
    • Yan Zhao
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-11

  • GlyT1 critically regulates excitatory neurotransmission and has thus emerged as a therapeutic target for schizophrenia. This study delineates the binding sites of the clinically trialed drugs iclepertin and sarcosine and elucidates how cholesterol modulates GlyT1 activity.

    • Na Li
    • Yiqing Wei
    • Yan Zhao
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-11

  • DUR3 absorbs low-concentration urea from soil and recycles urea from senescent leaves. Here, authors resolve the DUR3 structure, clarify how urea is specifically recognized, and elucidate the proton-driven urea transport mechanisms of DUR3.

    • Weidong An
    • Yiwei Gao
    • Xuejun C. Zhang
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-9

  • Here the authors show structures of the vesicular acetylcholine transporter in its apo state and in complex with the substrate acetylcholine and the inhibitor vesamicol, providing insights into substrate recognition, proton coupling and conformational transition mechanisms.

    • Qiao Ma
    • Kunpeng Ma
    • Yan Zhao
    Research
    Nature Structural & Molecular Biology
    Volume: 32, P: 818-827

  • CaV1.2 is crucial in cardiac, vascular and neuronal function, serving as a target for many drugs. Here, authors identify the binding site of herb-derived drug tetrandrine, and explore inhibitory mechanism of L/T-type selective DHP drug benidipine.

    • Yiqing Wei
    • Zhuoya Yu
    • Yan Zhao
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-11

  • Structural analyses of the human dopamine transporter in apo and substrate-bound states and in complex with drugs and inhibitors reveal key binding residues and conformational transitions that occur during substrate transport.

    • Yue Li
    • Xianping Wang
    • Yan Zhao
    Research
    Nature
    Volume: 632, P: 686-694

  • Cryo-electron microscopy structures of the noradrenaline transporter (NET) reveal binding modes of adrenaline, coordination of sodium and chloride ion binding and the binding sites and mechanisms of inhibition by conotoxin, bupropion and ziprasidone.

    • Tuo Hu
    • Zhuoya Yu
    • Yan Zhao
    Research
    Nature
    Volume: 632, P: 930-937

  • The authors report the structures of human CHT1 in the outward-open, inward-occluded and inward-open states, reveal the mechanism of HC-3 inhibition and choline recognition and elucidate the regulatory role of the intracellular helix IH1.

    • Yunlong Qiu
    • Yiwei Gao
    • Yan Zhao
    Research
    Nature Structural & Molecular Biology
    Volume: 31, P: 701-709